Eon Nimo Dipin Injection

Adult dosage

(Oral: tablets) ○ Adults Swallow whole without chewing, with a small amount of liquid, regardless of meals. 1. Ischemic neurologic disorders due to cerebral vasospasm: After administering nimodipine injection for 5-14 days after hemorrhage, administer nimodipine 60㎎ orally 6 times daily at 4-hour intervals for 7 days. 2. Cerebral dysfunction: Administer 30㎎ of this medicine 3 times daily. Maintain an interval of at least 4 hours between doses. Do not use the oral and injectable formulations concomitantly. Adjust the dose as appropriate according to age and symptoms. (Injection) 1. Intravenous infusion Start at 1㎎(5㎖) per hour (approximately 15㎍/kg of body weight) and administer over at least 2 hours. After 2 hours, the rate may be increased to 2㎎(10㎖) per hour (approximately 30㎍/kg of body weight), provided the patient tolerates the medicine and, in particular, no marked decrease in blood pressure occurs. In patients weighing less than 70㎏ or with unstable blood pressure, treatment may be started at 0.5㎎(2.5㎖) per hour. Reduce the dose if the medicine is not tolerated. Infuse with fluids and blood through a catheter using an infusion pump in an extracorporeal circulation system. To adequately dilute this medicine, the concomitant infusion volume should be at least 1,000㎖ per day. Continue administration during anesthesia, surgery, and angiography. Because the active ingredient in this medicine is adsorbed onto PVC, use polyethylene tubing. 2. Intra-arachnoid administration Dilute 1㎖ of this medicine in 19㎖ of Ringer's solution. Warm the diluted medicine to approximately body temperature (37℃) and administer by infusion during surgery. 3. Duration of administration 1) Prevention Start intravenous administration within 4 days after hemorrhage and continue during the period when vasospasm is likely to occur, i.e., until 10-14 days after hemorrhage. Then continue oral administration for 7 days at 60㎎ per dose, 6 times daily at 4-hour intervals. 2) Treatment If neurologic disorders due to vasospasm have already developed after hemorrhage, start treatment as soon as possible and administer intravenously for at least 5 to 14 days. After intravenous administration, continue oral administration for 7 days at 60㎎ per dose, 6 times daily at 4-hour intervals. If the cause of the hemorrhage is treated surgically during treatment or prevention, continue intravenous administration for at least 5 days after surgery. The total duration of continuous administration must not exceed 21 days. Do not use the injection and oral formulations concomitantly. Adjust the dose as appropriate according to age and symptoms.

This drug should not be used in patients who are allergic to this drug or its ingredients. Women who are pregnant or may become pregnant should not take this medication. Patients with cerebral edema or elevated intracranial pressure, very low blood pressure, and impaired liver or kidney function should use this drug cautiously. Side effects such as nausea, gastrointestinal disturbances, headache, dizziness, blood pressure drops, flushing, and excessive sweating may occur when taking this medication. Rarely, hypersensitivity reactions such as thrombocytopenia, thrombophlebitis, worsening kidney function, elevation of liver enzymes, and skin rashes may occur. Dizziness may occur with this medication; therefore, caution should be exercised when driving or operating hazardous machinery. In cases of elevated intracranial pressure or cerebral edema, more careful monitoring is required. This medication contains alcohol, so special caution should be taken by individuals with a history of alcohol use disorder, those with problems in alcohol metabolism, pregnant or breastfeeding women, children, patients with liver disease, and those with epilepsy. This medication may interact with other drugs; therefore, it should be administered cautiously, particularly when used in combination with antidepressants, antihypertensives, antiepileptics, and nephrotoxic drugs. The safety during pregnancy has not been established, and this drug is also excreted in breast milk, so it is advisable to avoid taking it while breastfeeding. In case of overdose, significant drops in blood pressure and irregular heartbeats may occur, as well as gastrointestinal discomfort and nausea, so dosing should be stopped immediately and emergency measures should be sought. This drug is sensitive to light, so it should be stored in containers that block light, and care should be taken to prevent exposure to light during administration. While this drug can help improve cerebral blood flow and alleviate conditions in patients with cerebral blood circulation disorders, it must be used according to a doctor's instruction.

• nausea
• gastrointestinal disorders
• intestinal obstruction
• headache
• dizziness
• hypotension
• vasodilation
• blood pressure reduction
• facial flushing
• warmth sensation

This drug is sensitive to light, so it should be stored in containers that block light. Also, it is best to store it at a temperature between 1°C and 30°C. By storing it this way, its efficacy and safety can be maintained.

Appearance

[For domestic use] Yellowish injection solution filled in a brown vial [For export] Brown vial filled with a yellowish clear solution

Package unit

50mL/vial × 1